Why Doctors Still Prescribe Brands When Generics Exist

Generic drugs are chemically identical to their brand-name counterparts, cost 80-85% less on average, and are required by the FDA to have the same active ingredient, strength, dosage form, and route of administration. Yet in Medicare Part D, 13.4% of prescriptions are still written for brand-name drugs — accounting for$185.46B of the $275.65B total spend. That's a massive premium paid for a label, not a molecule.

The Scale of the Problem

To understand why generic adoption matters, consider the math: if every brand-name prescription that has a generic equivalent were switched, Medicare Part D could save an estimated $50-80 billion annually. That's enough to fund the entire Veterans Affairs healthcare system.

The 40,249 providers we've identified as "brand-heavy" prescribers — those writing brands at significantly above their specialty's average — represent a concentrated opportunity for savings. Some prescribe brands for 50%, 70%, even 100% of their prescriptions.

Why Brand Loyalty Persists

1. Pharmaceutical Marketing

The pharmaceutical industry spends approximately $20 billion annually on marketing to healthcare providers. This includes:

• Sales representatives: ~60,000 drug reps in the US make regular visits to prescriber offices
• Free samples: $18+ billion worth of free drug samples distributed annually — these create familiarity and habit
• Continuing Medical Education (CME): Industry-sponsored education events that subtly promote brand drugs
• Direct payments: Consulting fees, speaking honoraria, and research grants tracked by the CMS Open Payments database

Research consistently shows that even small gifts and interactions with drug reps increase brand-name prescribing. A 2016 study in JAMA Internal Medicine found that a single industry-sponsored meal was associated with higher prescribing rates of the promoted drug.

2. Patient Demand and Perception

Some patients specifically request brand-name drugs, often influenced by direct-to-consumer advertising (the US is one of only two countries that allows DTC pharmaceutical ads). Common patient beliefs include:

• "The brand version works better for me" (nocebo effect — belief that the generic is inferior causes perceived side effects)
• "I don't trust generic manufacturers" (despite FDA equivalence requirements)
• "My doctor knows best — they prescribed the brand for a reason"
• Insurance copay structures that sometimes make brands affordable (copay cards, manufacturer coupons)

3. Inertia and Habit

Perhaps the most powerful factor is simply inertia. A patient started on a brand drug years ago stays on it. The prescriber re-authorizes the same prescription without reviewing alternatives. The pharmacy fills what's written. No one in the chain has a strong incentive to change — especially when the PBM may actually prefer the brand (due to rebates, as discussed in our PBM analysis).

4. Legitimate Clinical Reasons

To be fair, there are cases where brand-name drugs are genuinely preferred:

• Narrow therapeutic index drugs (e.g., thyroid medications, anticonvulsants) where small differences in absorption matter
• No generic available — many expensive drugs are still under patent
• Drug delivery systems — inhalers, patches, and injectors where the device matters as much as the drug
• Documented intolerance — some patients genuinely react to inactive ingredients in specific generics

The Most Expensive Brand Drugs in Medicare

These are the drugs costing Medicare the most — many of which have no generic equivalent yet, but some of which do:

These 15 high-cost drugs represent $37.04B in Medicare spending. Where biosimilars or generic alternatives exist, switching could save billions.

Which Specialties Are Worst at Generic Adoption?

Specialty matters enormously for brand-vs-generic patterns. Some specialties prescribe almost exclusively high-cost brands because that's the nature of their drugs (oncology). Others prescribe brands where cheap generics exist (family practice providers with high brand rates). We can use cost-per-claim as a proxy — specialties with very high cost per claim are typically prescribing expensive brands or specialty drugs:

The Biosimilar Opportunity

Biosimilars are the "generics" of biologic drugs — complex proteins that can't be exactly copied but can be manufactured to be clinically equivalent. The biosimilar market represents one of the largest savings opportunities in Medicare:

• Humira (adalimumab) — Multiple biosimilars now available at 50-85% discount. Medicare spent $2.17B on adalimumab products.
• Insulin — Biosimilar insulins offer 50-70% savings but adoption varies wildly by provider
• Oncology biologics — Biosimilar versions of Avastin, Herceptin, and Rituxan are available but face prescriber resistance

What Drives Change?

Interventions That Work

• Electronic prescribing with generic prompts: When EHR systems suggest generic alternatives at the point of prescribing, adoption increases 20-30%
• Academic detailing: Non-commercial pharmacist educators visiting prescribers to discuss evidence-based prescribing (shown to reduce brand prescribing by 10-15%)
• Formulary design: Higher copays for brands with generic equivalents nudge patients and providers toward generics
• Transparency: Public reporting of prescriber-level brand rates (as we do on OpenPrescriber) creates social pressure for change

Interventions That Don't Work

• Information alone: Simply telling doctors "generics are equivalent" doesn't change behavior — habits and relationships with drug reps are stronger
• One-time educational events: Brief interventions show no lasting effect on prescribing patterns
• Patient copay cards: Manufacturer copay assistance for brands actually increases brand use by eliminating the patient's price signal

The Path Forward

Improving generic adoption in Medicare Part D requires a multi-pronged approach:

1. Require generic-first prescribing for conditions where generics exist — prescribers should have to justify brand-name prescriptions
2. Reform PBM incentives that favor brands over generics (see our PBM analysis)
3. Ban manufacturer copay cards for drugs with generic equivalents in Medicare
4. Mandate biosimilar adoption timelines when biosimilars are FDA-approved
5. Public transparency — prescriber-level brand rates should be prominently displayed (as we do here)

The data is clear: billions of Medicare dollars are spent on brand-name drugs when cheaper, equivalent alternatives exist. The barriers to generic adoption are not clinical — they're structural, behavioral, and financial. And they're fixable.

International Comparison: How the US Falls Behind

The United States has one of the lowest generic adoption rates among wealthy nations. This isn't because American patients or doctors are uniquely resistant to generics — it's because the US pharmaceutical system creates structural incentives against generic use:

Case Study: The Humira Biosimilar Rollout

The introduction of Humira (adalimumab) biosimilars in 2023 provides a real-time case study in the challenges of generic/biosimilar adoption. Despite multiple FDA-approved biosimilars at 50-85% discounts:

• Biosimilar uptake reached only ~15% after the first year on the US market
• AbbVie's "patent thicket" of 100+ patents delayed competition for years
• PBMs initially kept branded Humira on preferred formulary tiers due to rebate agreements
• Many prescribers were hesitant to switch stable patients to biosimilars despite equivalent efficacy

Compare this to Europe, where biosimilar adalimumab captured over 80% of the market within 18 months. The difference isn't clinical — it's systemic.

Explore Related Analysis

• Brand vs Generic: The Prescribing Gap That Costs Billions
• PBMs: The Middlemen Driving Drug Costs
• The Drugs That Cost Medicare Billions
• The Most Expensive Prescribers
• Which Specialties Drive the Most Spending?